The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Feb. 1, 9:42 AM

Slide #24. Puma Biotechnology, Inc. Secondary Offering

Company: Puma Biotechnology, Inc. (NYSE:PBYI)
Date announced: 1/20/2015
Shares Offered: 1,000,000
Date of Pricing: 1/21/2015
Price Per Share: $190.00
Secondary Offering Details: Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, today announced that it is commencing an underwritten registered public offering of 1,000,000 shares of its common stock. Puma Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional 150,000 shares of its common stock. All of the shares are being offered by Puma Biotechnology. - updated 1/21 - Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, announced the pricing of an underwritten registered public offering of 1,000,000 shares of its common stock at $190.00 per share. The Company has granted the underwriters for the offering a 30-day option to purchase up to 150,000 additional shares of its common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about January 27, 2015, subject to customary closing conditions.

Puma Biotechnology is a development stage biopharmaceutical company that acquires and develops products for the treatment of several forms of cancer. Co. focuses on in-licensing drug candidates that are undergoing or has already completed initial clinical testing for the treatment of cancer and then further develop those drug candidates for commercial use. Co. is licensed the rights to three drug candidates: PB272 (neratinib (oral)), which is for the treatment of advanced breast cancer patients, non-small cell lung cancer patients and patients with tumors; PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients; and PB357, which serves as a backup compound to PB272.
Open the PBYI Page at The Online Investor »

Company Name:  Puma Biotechnology, Inc.
Website:  www.pumabiotechnology.com
Sector:  Biotechnology
Number of ETFs Holding PBYI:  22
Total Market Value Held by ETFs:  $228.34M
Total Market Capitalization:  $6.82B
% of Market Cap. Held by ETFs:  3.35%
 

Open the PBYI Page at The Online Investor (in a new window) »

February 1, 2015    9:42 AM Eastern
Quotes delayed 20 minutes



Buy (3.25 out of 4)
58th percentile
(ranked higher than approx. 58% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.